KR100483300B1 - 선택적 환형 펩타이드 - Google Patents

선택적 환형 펩타이드 Download PDF

Info

Publication number
KR100483300B1
KR100483300B1 KR10-2003-7002931A KR20037002931A KR100483300B1 KR 100483300 B1 KR100483300 B1 KR 100483300B1 KR 20037002931 A KR20037002931 A KR 20037002931A KR 100483300 B1 KR100483300 B1 KR 100483300B1
Authority
KR
South Korea
Prior art keywords
lys
asp
hydrogen
phe
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2003-7002931A
Other languages
English (en)
Korean (ko)
Other versions
KR20030061788A (ko
Inventor
첸리
층아드리안와이-힝
추신-지
단호왈리드
스위스토크조셉
왕야오
야갈로프케이쓰알란
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20030061788A publication Critical patent/KR20030061788A/ko
Application granted granted Critical
Publication of KR100483300B1 publication Critical patent/KR100483300B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2003-7002931A 2000-08-30 2001-08-21 선택적 환형 펩타이드 Expired - Fee Related KR100483300B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22918400P 2000-08-30 2000-08-30
US60/229,184 2000-08-30
PCT/EP2001/009630 WO2002018437A2 (en) 2000-08-30 2001-08-21 Cyclic peptides having melanocortin-4 receptor agonist activity

Publications (2)

Publication Number Publication Date
KR20030061788A KR20030061788A (ko) 2003-07-22
KR100483300B1 true KR100483300B1 (ko) 2005-04-15

Family

ID=22860145

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7002931A Expired - Fee Related KR100483300B1 (ko) 2000-08-30 2001-08-21 선택적 환형 펩타이드

Country Status (35)

Country Link
US (1) US7045591B2 (https=)
EP (1) EP1315750B1 (https=)
JP (1) JP4217069B2 (https=)
KR (1) KR100483300B1 (https=)
CN (1) CN100491396C (https=)
AR (2) AR030504A1 (https=)
AT (1) ATE353918T1 (https=)
AU (2) AU2001284026B2 (https=)
BR (1) BR0113637A (https=)
CA (1) CA2420058C (https=)
CY (1) CY1106562T1 (https=)
CZ (1) CZ2003584A3 (https=)
DE (1) DE60126624T2 (https=)
DK (1) DK1315750T3 (https=)
EC (1) ECSP034503A (https=)
ES (1) ES2280393T3 (https=)
HR (1) HRP20030126B1 (https=)
HU (1) HUP0303078A3 (https=)
IL (2) IL154575A0 (https=)
JO (1) JO2454B1 (https=)
MA (1) MA27681A1 (https=)
MX (1) MXPA03001721A (https=)
MY (1) MY137457A (https=)
NO (1) NO20030916D0 (https=)
NZ (1) NZ523989A (https=)
PA (1) PA8527201A1 (https=)
PE (1) PE20020483A1 (https=)
PL (1) PL366630A1 (https=)
PT (1) PT1315750E (https=)
RU (1) RU2239642C1 (https=)
SI (1) SI1315750T1 (https=)
TW (1) TWI248941B (https=)
WO (1) WO2002018437A2 (https=)
YU (1) YU15603A (https=)
ZA (1) ZA200301015B (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960646B2 (en) * 2001-07-12 2005-11-01 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptors agonists
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
BRPI0409976A (pt) * 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
EP1644022A1 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
PL1751273T3 (pl) * 2004-04-08 2011-07-29 Astellas Pharma Inc Związek WS727713
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CN101052650A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
JP2008519006A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
US20110098213A1 (en) * 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
CN101052649A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的肽类
CN101203527A (zh) * 2005-05-31 2008-06-18 耶路撒冷希伯来大学伊森姆研究发展公司 主链环化的促黑皮质素激素（αMSH）类似物
WO2006135930A2 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US7671112B2 (en) * 2005-07-15 2010-03-02 3M Innovative Properties Company Method of making fluoropolymer dispersion
US20080015304A1 (en) 2006-07-13 2008-01-17 Klaus Hintzer Aqueous emulsion polymerization process for producing fluoropolymers
GB2430437A (en) * 2005-09-27 2007-03-28 3M Innovative Properties Co Method of making a fluoropolymer
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CA2673229A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Methods for the synthesis of cyclic peptides
EP2132143B1 (en) * 2007-02-16 2012-12-26 3M Innovative Properties Company System and process for the removal of fluorochemicals from water
US20080264864A1 (en) 2007-04-27 2008-10-30 3M Innovative Properties Company PROCESS FOR REMOVING FLUORINATED EMULSIFIER FROM FLUOROPOLMER DISPERSIONS USING AN ANION-EXCHANGE RESIN AND A pH-DEPENDENT SURFACTANT AND FLUOROPOLYMER DISPERSIONS CONTAINING A pH-DEPENDENT SURFACTANT
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
WO2009011261A1 (ja) 2007-07-19 2009-01-22 Tokuyama Corporation ヒダントイン環を有する化合物及びその製造方法
AU2009228637B2 (en) * 2008-03-27 2013-12-19 Grunenthal Gmbh (Hetero-)aryl cyclohexane derivatives
CA2719735A1 (en) 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
EP2970388B1 (en) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
CU20170038A7 (es) * 2014-09-26 2017-10-05 Bayer Pharma AG Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
US10653743B2 (en) 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
CN106496005B (zh) * 2016-10-20 2019-04-09 上海毕得医药科技有限公司 一种4-(4-氯苯基)环己酮的合成方法
US10745444B2 (en) * 2017-04-17 2020-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN118530294B (zh) * 2024-05-10 2025-02-14 浙江大学 一种芳基二胺固载连接子、其前体以及制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5858972A (en) 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands

Also Published As

Publication number Publication date
HUP0303078A3 (en) 2012-02-28
DK1315750T3 (da) 2007-06-11
SI1315750T1 (sl) 2007-06-30
BR0113637A (pt) 2004-02-25
JP2004507558A (ja) 2004-03-11
ECSP034503A (es) 2003-04-25
CA2420058C (en) 2009-04-07
CA2420058A1 (en) 2002-03-07
IL154575A0 (en) 2003-09-17
JO2454B1 (en) 2008-10-09
HUP0303078A2 (hu) 2003-12-29
TWI248941B (en) 2006-02-11
MXPA03001721A (es) 2003-05-27
ATE353918T1 (de) 2007-03-15
WO2002018437A3 (en) 2002-06-06
AU8402601A (en) 2002-03-13
US7045591B2 (en) 2006-05-16
US20020143141A1 (en) 2002-10-03
AR030504A1 (es) 2003-08-20
CN100491396C (zh) 2009-05-27
AU2001284026B2 (en) 2007-03-01
NO20030916L (no) 2003-02-27
DE60126624T2 (de) 2007-11-22
EP1315750A2 (en) 2003-06-04
HRP20030126B1 (en) 2009-01-31
CZ2003584A3 (cs) 2003-08-13
MY137457A (en) 2009-01-30
WO2002018437A2 (en) 2002-03-07
KR20030061788A (ko) 2003-07-22
PA8527201A1 (es) 2002-04-25
EP1315750B1 (en) 2007-02-14
CY1106562T1 (el) 2012-01-25
NO20030916D0 (no) 2003-02-27
YU15603A (sh) 2006-05-25
AR061422A2 (es) 2008-08-27
MA27681A1 (fr) 2006-01-02
PE20020483A1 (es) 2002-06-06
PT1315750E (pt) 2007-05-31
DE60126624D1 (de) 2007-03-29
JP4217069B2 (ja) 2009-01-28
PL366630A1 (en) 2005-02-07
IL154575A (en) 2008-12-29
HRP20030126A2 (en) 2005-10-31
RU2239642C1 (ru) 2004-11-10
NZ523989A (en) 2004-08-27
CN1451017A (zh) 2003-10-22
ES2280393T3 (es) 2007-09-16
ZA200301015B (en) 2004-05-05

Similar Documents

Publication Publication Date Title
KR100483300B1 (ko) 선택적 환형 펩타이드
JP3938690B2 (ja) メラノコルチン−４受容体（ｍｃ４−ｒ）アゴニスト活性を持つ選択性線状ペプチド
AU2001284026A1 (en) Cyclic peptides having melanocortin-4 receptor agonist activity
US6767887B1 (en) Exendin analogues, processes for their preparation and medicaments containing them
CA2368431C (en) Melanocortin receptor ligands
US5674839A (en) Cyclic analogs of alpha-MSH fragments
JPH0826077B2 (ja) 線状および環状アルファ―メラノトロピン類以体
CN102596228A (zh) 神经肽-2受体(y-2r)激动剂
JP2025508820A (ja) Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用
US6673769B2 (en) Lanthionine bridged peptides
CA2405704C (en) Bombesin analogs for treatment of cancer
CA2405724C (en) Substance p analogs for the treatment of cancer
US5502164A (en) Peptide compounds having therapeutic activity
CN121285571A (zh) Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
HK40095414A (en) Crf2 receptor agonists and their use in therapy

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20110330

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120407

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120407

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000